Comparative Performance of the GeeniusTM HIV-1/HIV-2 Supplemental Test in Florida's Public Health Testing Population

Highlights • The Geenius HIV-1/HIV-2 Supplemental assay (Geenius) is the first non-subjective supplemental immunoassay in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2017
Main Authors: Fordan, Sally, Bennett, Berry, Lee, Meghan, Crowe, Susanne
Format: Article
Language:English
Subjects:
Allergy and Immunology
Infectious Disease
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • The Geenius HIV-1/HIV-2 Supplemental assay (Geenius) is the first non-subjective supplemental immunoassay in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay (Multispot) and offers significant advantages over the subjective Multispot assay. • Based on this study, the use of Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance but also illustrates the need for HIV-2 RNA NAT or an equivalent test to confirm HIV-2 infections.
ISSN:1386-6532
DOI:10.1016/j.jcv.2017.04.005